# Champions Oncology, Inc.: financial statements, quarterly

CSBR · Nasdaq · CIK 771856 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/csbr.md) · [Financials](/companies/csbr/financials.md) · [Filings](/companies/csbr/filings.md) · [Insiders](/companies/csbr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/csbr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.6](/filings/0001628280-24-051389.md) | [12.0](/filings/0001628280-25-012941.md) | [14.0 d](/filings/0001628280-25-035765.md) | [14.1](/filings/0000771856-25-000023.md) | [13.5](/filings/0001628280-25-057082.md) | [17.0](/filings/0001628280-26-017345.md) | [12.4 d](/filings/0001628280-26-049834.md) | [14.0](/filings/0001628280-26-061519.md) | [15.0](/filings/0001628280-25-057082.md) | [16.6](/filings/0001628280-26-017345.md) | [13.8 d](/filings/0001628280-26-049834.md) | [15.2](/filings/0001628280-26-061519.md) |
| Cost of revenue | $m | [6.6](/filings/0001628280-24-051389.md) | [7.8](/filings/0001628280-25-012941.md) | [7.3 d](/filings/0001628280-25-035765.md) | [7.1](/filings/0000771856-25-000023.md) | [7.4](/filings/0001628280-25-057082.md) | [6.6](/filings/0001628280-26-017345.md) | [7.3 d](/filings/0001628280-26-049834.md) | [8.0](/filings/0001628280-26-061519.md) | [7.3](/filings/0001628280-25-057082.md) | [8.8](/filings/0001628280-26-017345.md) | [6.8 d](/filings/0001628280-26-049834.md) | [7.5](/filings/0001628280-26-061519.md) |
| Research and development | $m | [2.5](/filings/0001628280-24-051389.md) | [2.2](/filings/0001628280-25-012941.md) | [2.1 d](/filings/0001628280-25-035765.md) | [1.5](/filings/0000771856-25-000023.md) | [1.7](/filings/0001628280-25-057082.md) | [1.7](/filings/0001628280-26-017345.md) | [2.0 d](/filings/0001628280-26-049834.md) | [2.1](/filings/0001628280-26-061519.md) | [2.6](/filings/0001628280-25-057082.md) | [2.3](/filings/0001628280-26-017345.md) | [2.1 d](/filings/0001628280-26-049834.md) | [2.3](/filings/0001628280-26-061519.md) |
| Operating income | $m | [(2.0)](/filings/0001628280-24-051389.md) | [(2.6)](/filings/0001628280-25-012941.md) | [(0.3) d](/filings/0001628280-25-035765.md) | [1.3](/filings/0000771856-25-000023.md) | [0.7](/filings/0001628280-25-057082.md) | [4.5](/filings/0001628280-26-017345.md) | [(2.0) d](/filings/0001628280-26-049834.md) | [(0.5)](/filings/0001628280-26-061519.md) | [0.2](/filings/0001628280-25-057082.md) | [(0.3)](/filings/0001628280-26-017345.md) | [(0.5) d](/filings/0001628280-26-049834.md) | [(0.4)](/filings/0001628280-26-061519.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-051389.md) | [0.0](/filings/0001628280-25-012941.md) | [(0.1) d](/filings/0001628280-25-035765.md) | [0.0](/filings/0000771856-25-000023.md) | [0.0](/filings/0001628280-25-057082.md) | [0.0](/filings/0001628280-26-017345.md) | [(0.1) d](/filings/0001628280-26-049834.md) | [0.0](/filings/0001628280-26-061519.md) | [0.0](/filings/0001628280-25-057082.md) | [0.0](/filings/0001628280-26-017345.md) | [0.2 d](/filings/0001628280-26-049834.md) | [0.0](/filings/0001628280-26-061519.md) |
| Net income | $m | [(2.1)](/filings/0001628280-25-012941.md) | [(2.5)](/filings/0001628280-25-012941.md) | [(0.1) d](/filings/0001628280-25-035765.md) | [1.3](/filings/0000771856-25-000023.md) | [0.7](/filings/0001628280-25-057082.md) | [4.5](/filings/0001628280-26-017345.md) | [(1.8) d](/filings/0001628280-26-049834.md) | [(0.5)](/filings/0001628280-26-061519.md) | [0.3](/filings/0001628280-25-057082.md) | [(0.3)](/filings/0001628280-26-017345.md) | [(0.7) d](/filings/0001628280-26-049834.md) | [(0.4)](/filings/0001628280-26-061519.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0001628280-24-051389.md) | [(0.19)](/filings/0001628280-25-012941.md) | not reported | [0.09](/filings/0000771856-25-000023.md) | [0.05](/filings/0001628280-25-057082.md) | [0.31](/filings/0001628280-26-017345.md) | not reported | [(0.03)](/filings/0000771856-25-000023.md) | [0.02](/filings/0001628280-25-057082.md) | [(0.02)](/filings/0001628280-26-017345.md) | not reported | not reported |
| Basic EPS | $ per share | [(0.15)](/filings/0001628280-24-051389.md) | [(0.19)](/filings/0001628280-25-012941.md) | not reported | [0.10](/filings/0000771856-25-000023.md) | [0.05](/filings/0001628280-25-057082.md) | [0.33](/filings/0001628280-26-017345.md) | not reported | [(0.03)](/filings/0001628280-26-061519.md) | [0.02](/filings/0001628280-25-057082.md) | [(0.02)](/filings/0001628280-26-017345.md) | not reported | [(0.03)](/filings/0001628280-26-061519.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.5](/filings/0001628280-23-041457.md) | [4.5](/filings/0001628280-24-011279.md) | [2.6](/filings/0001628280-25-012941.md) | [2.9](/filings/0001628280-24-040312.md) | [2.8](/filings/0001628280-24-051389.md) | [3.2](/filings/0001628280-25-012941.md) | [9.8](/filings/0001628280-26-017345.md) | [10.3](/filings/0000771856-25-000023.md) | [8.5](/filings/0001628280-25-057082.md) | [7.1](/filings/0001628280-26-017345.md) | [4.9](/filings/0001628280-26-061519.md) | [4.4](/filings/0001628280-26-061519.md) |
| Current assets | $m | [14.0](/filings/0001628280-23-041457.md) | [13.2](/filings/0001628280-24-011279.md) | [13.6](/filings/0001628280-25-035765.md) | [13.2](/filings/0001628280-24-040312.md) | [14.1](/filings/0001628280-24-051389.md) | [19.7](/filings/0001628280-25-012941.md) | [22.4](/filings/0001628280-26-049834.md) | [21.0](/filings/0000771856-25-000023.md) | [21.3](/filings/0001628280-25-057082.md) | [20.2](/filings/0001628280-26-017345.md) | [19.2](/filings/0001628280-26-061519.md) | [19.3](/filings/0001628280-26-061519.md) |
| Total assets | $m | [28.3](/filings/0001628280-23-041457.md) | [26.8](/filings/0001628280-24-011279.md) | [26.1](/filings/0001628280-25-035765.md) | [24.9](/filings/0001628280-24-040312.md) | [25.2](/filings/0001628280-24-051389.md) | [30.6](/filings/0001628280-25-012941.md) | [32.3](/filings/0001628280-26-049834.md) | [30.5](/filings/0000771856-25-000023.md) | [30.2](/filings/0001628280-25-057082.md) | [28.4](/filings/0001628280-26-017345.md) | [27.0](/filings/0001628280-26-061519.md) | [33.3](/filings/0001628280-26-061519.md) |
| Current liabilities | $m | [21.0](/filings/0001628280-23-041457.md) | [22.0](/filings/0001628280-24-011279.md) | [21.5](/filings/0001628280-25-035765.md) | [19.2](/filings/0001628280-24-040312.md) | [18.9](/filings/0001628280-24-051389.md) | [19.9](/filings/0001628280-25-012941.md) | [23.9](/filings/0001628280-26-049834.md) | [22.7](/filings/0000771856-25-000023.md) | [22.1](/filings/0001628280-25-057082.md) | [20.7](/filings/0001628280-26-017345.md) | [19.9](/filings/0001628280-26-061519.md) | [18.7](/filings/0001628280-26-061519.md) |
| Total liabilities | $m | [28.2](/filings/0001628280-23-041457.md) | [28.8](/filings/0001628280-24-011279.md) | [28.0](/filings/0001628280-25-035765.md) | [25.3](/filings/0001628280-24-040312.md) | [24.6](/filings/0001628280-24-051389.md) | [25.2](/filings/0001628280-25-012941.md) | [28.6](/filings/0001628280-26-049834.md) | [27.0](/filings/0000771856-25-000023.md) | [25.9](/filings/0001628280-25-057082.md) | [24.1](/filings/0001628280-26-017345.md) | [22.9](/filings/0001628280-26-061519.md) | [28.8](/filings/0001628280-26-061519.md) |
| Shareholders' equity | $m | [0.1](/filings/0001628280-25-012941.md) | [(2.1)](/filings/0001628280-25-012941.md) | [(1.9)](/filings/0001628280-25-035765.md) | [(0.3)](/filings/0001628280-25-012941.md) | [0.7](/filings/0001628280-25-012941.md) | [5.5](/filings/0001628280-25-012941.md) | [3.8](/filings/0001628280-26-049834.md) | [3.5](/filings/0000771856-25-000023.md) | [4.2](/filings/0001628280-25-057082.md) | [4.3](/filings/0001628280-26-017345.md) | [3.9](/filings/0001628280-26-061519.md) | [3.9](/filings/0001628280-26-061519.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [589 d](/filings/0001628280-24-051389.md) | [(919) d](/filings/0001628280-25-012941.md) | [(1,816) d](/filings/0001628280-25-035765.md) | [311](/filings/0000771856-25-000023.md) | [(283) d](/filings/0001628280-25-057082.md) | [490 d](/filings/0001628280-26-017345.md) | [6,868 d](/filings/0001628280-26-049834.md) | [600](/filings/0001628280-26-061519.md) | [(1,735) d](/filings/0001628280-25-057082.md) | [(1,339) d](/filings/0001628280-26-017345.md) | [(1,998) d](/filings/0001628280-26-049834.md) | [(492)](/filings/0001628280-26-061519.md) |
| Capital expenditure | $k | [79.0 d](/filings/0001628280-24-051389.md) | [92.0 d](/filings/0001628280-25-012941.md) | [(3.0) d](/filings/0001628280-25-035765.md) | [0.0](/filings/0000771856-25-000023.md) | [94.0 d](/filings/0001628280-25-057082.md) | [42.0 d](/filings/0001628280-26-017345.md) | [253 d](/filings/0001628280-26-049834.md) | [46.0](/filings/0001628280-26-061519.md) | [242 d](/filings/0001628280-25-057082.md) | [37.0 d](/filings/0001628280-26-017345.md) | [239 d](/filings/0001628280-26-049834.md) | [55.0](/filings/0001628280-26-061519.md) |
| Share repurchases | $k | [32.0 d](/filings/0001628280-24-051389.md) | [0.0 d](/filings/0001628280-25-012941.md) | [0.0 d](/filings/0001628280-25-035765.md) | [0.0](/filings/0001628280-24-040312.md) | [0.0 d](/filings/0001628280-24-051389.md) | [0.0 d](/filings/0001628280-25-012941.md) | [0.0 d](/filings/0001628280-25-035765.md) | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-07-31) | Q2 FY2023 (2022-10-31) | Q3 FY2023 (2023-01-31) | Q1 FY2024 (2023-07-31) | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.5](/filings/0001628280-23-032212.md) | [13.5](/filings/0001628280-23-041457.md) | [13.6](/filings/0001628280-24-011279.md) | [13.5](/filings/0001628280-24-040312.md) | [13.5](/filings/0001628280-24-051389.md) | [13.6](/filings/0001628280-25-012941.md) | [14.0](/filings/0000771856-25-000023.md) | [14.0](/filings/0001628280-25-057082.md) | [14.4](/filings/0001628280-26-017345.md) | [13.8](/filings/0000771856-25-000023.md) | [14.5](/filings/0001628280-25-057082.md) | [13.9](/filings/0001628280-26-017345.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,918,569 at 2026-09-09, from the cover of the [10-Q filed 2026-09-11](/filings/0001628280-26-061519.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.